PCRX

Pacira BioSciences, Inc.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001396814
$22.99 -1.58% $904.6M
Insider Selling Cluster (2 insiders)9 New Institutional Positions10 Institutional Exits
Vol
Market Cap$904.6M
Cap SizeSmall Cap
Analyst ConsensusBuy (69%)
Inst. Holders50 funds
Inst. Value$650.1M
Inst. Activity9 buys / 10 sells
Insider Activity0B / 10S
Insider Net $-$1.4M
SEC Reports10
Press Releases3
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001396814·Prev Close $23.36

Recent Activity

Jun 13, 2026 SEC
Pacira BioSciences saw two insider sales totaling $372K over a week, including the Chief Administrative Officer and SVP
CLUSTER — Impact 3/10
Jun 11, 2026 Insider
RIKER LAUREN sold 6,115 shares
Senior Vice President, Finance @ $23.50 ($143.7K)
Jun 10, 2026 Insider
Brege Laura was granted 6,405 shares
Director
Jun 10, 2026 Insider
Froimson Mark was granted 6,405 shares
Director
Jun 5, 2026 SEC
Pacira BioSciences issued a DEFA14A press release reminding stockholders to vote FOR management's three director nominee
DEFA14A — Impact 6/10
Jun 4, 2026 SEC
Kristen Williams, an officer of Pacira BioSciences, filed a Form 144 intent to sell 10,259 shares of common stock, value
144 — Impact 2/10
Inst.
FIRST TRUST ADVISORS LP — ADD
300,632 shares ($6.8M)
Inst.
VICTORY CAPITAL MANAGEMENT INC — TRIM
235,090 shares ($5.3M)

Price Targets

$29.67 +29.0% upside Strong Buy
Current $22.99 Low $23.00 Median $28.50 High $38.00 6 analysts
$23.00 $38.00

Analyst Ratings

Buy69% buy · 13 analysts
3Strong Buy
6Buy
3Hold
1Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
May 1, 2026 RBC Capital MAINTAIN Sector Perform → Sector Perform
May 1, 2026 Needham MAINTAIN Buy → Buy
Mar 26, 2026 Barclays MAINTAIN Equal-Weight → Equal-Weight
Jan 9, 2026 HC Wainwright & Co. REITERATE Buy → Buy
Jan 9, 2026 Needham MAINTAIN Buy → Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $0.65 ▲ +2.4% $0.52 — $0.76 -13% YoY 6
Next Q $0.76 ▲ +1.3% $0.64 — $0.87 8% YoY 6
Current FY $2.88 ▲ +0.7% $2.74 — $2.98 9% YoY 6
Next FY $3.65 ▲ +0.9% $3.18 — $4.01 27% YoY 6

Latest Reports

NEUTRAL CLUSTER 3/10
Pacira BioSciences saw two insider sales totaling $372K over a week, including the Chief Administrative Officer and SVP
Jun 13, 2026
MIXED DEFA14A 6/10
Pacira BioSciences issued a DEFA14A press release reminding stockholders to vote FOR management's three director nominee
Jun 5, 2026
MIXED Press 7/10
Pacira BioSciences issued a press release urging stockholders to vote for its board nominees at the June 9 annual meetin
May 20, 2026

Top Institutional Holders

FundValueMove
BlackRock, Inc.$152.2M—
VANGUARD PORTFOLIO MANAGEMENT LLC$56.5M—
DIMENSIONAL FUND ADVISORS LP$46.6M—
D. E. Shaw &$44.8M—
STATE STREET CORP$43.4M—

Recent Insider Trades

DateInsiderTypeValue
Jun 11, 2026RIKER LAURENSELL$143.7K
Jun 10, 2026Brege LauraA$0.00
Jun 10, 2026Froimson MarkA$0.00
Jun 10, 2026CHRISTIE CHRISTOPHERA$0.00
Jun 10, 2026WIGGANS THOMASA$0.00
50 institutional holders with $650.1M total value (28,756,064 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, DIMENSIONAL. Net selling activity: 10 institutions trimmed/exited vs 9 added.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1BlackRock, Inc.6,735,343$152.2M23.4%—
2VANGUARD PORTFOLIO MANAGEMENT LLC2,501,286$56.5M8.7%—
3DIMENSIONAL FUND ADVISORS LP2,060,597$46.6M7.2%—
4D. E. Shaw & Co., Inc.1,982,724$44.8M6.9%—
5STATE STREET CORP1,919,610$43.4M6.7%—
6RENAISSANCE TECHNOLOGIES LLC1,825,501$41.3M6.3%—
7VANGUARD CAPITAL MANAGEMENT LLC1,784,049$40.3M6.2%—
8GOLDMAN SACHS GROUP INC1,569,916$35.5M5.5%—
9MORGAN STANLEY1,392,548$31.5M4.8%—
10CITADEL ADVISORS LLC797,281$18.0M2.8%—
11CHARLES SCHWAB INVESTMENT MANAGEMENT INC732,042$16.5M2.5%—
12TWO SIGMA INVESTMENTS, LP526,851$11.9M1.8%ADD +93.9%
13WELLINGTON MANAGEMENT GROUP LLP478,383$10.8M1.7%—
14DEUTSCHE BANK AG\391,677$8.9M1.4%NEW
15FIRST TRUST ADVISORS LP300,632$6.8M1.0%ADD +59.2%
16BARCLAYS PLC282,108$6.4M1.0%—
17VANGUARD FIDUCIARY TRUST CO267,793$6.1M0.9%—
18Invesco Ltd.237,580$5.4M0.8%TRIM -52.7%
19VICTORY CAPITAL MANAGEMENT INC235,090$5.3M0.8%TRIM -31.3%
20BANK OF AMERICA CORP /DE/188,437$4.3M0.7%—

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
FIRST TRUST ADVISORS LPADD188,889300,632+59.2%$6.8M2026-Q1
VICTORY CAPITAL MANAGEMENT INCTRIM342,313235,090-31.3%$5.3M2026-Q1
BALYASNY ASSET MANAGEMENT L.P.NEAR_EXIT945,979106,418-88.8%$2.4M2026-Q1
EXCHANGE TRADED CONCEPTS, LLCADD76,83897,286+26.6%$2.2M2026-Q1
FMR LLCADD73,89693,481+26.5%$2.1M2026-Q1
Trexquant Investment LPDOUBLED15,66491,633+485.0%$2.1M2026-Q1
Nuveen, LLCTRIM251,98489,806-64.4%$2.0M2026-Q1
Gotham Asset Management, LLCADD32,92844,939+36.5%$1.0M2026-Q1
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPTRIM53,19836,966-30.5%$835.4K2026-Q1
Vident Advisory, LLCADD23,57134,113+44.7%$771.0K2026-Q1
HighTower Advisors, LLCADD23,97230,506+27.3%$689.4K2026-Q1
Verition Fund Management LLCTRIM85,38929,919-65.0%$676.2K2026-Q1
VOLORIDGE INVESTMENT MANAGEMENT, LLCNEAR_EXIT234,44219,762-91.6%$446.6K2026-Q1
MANUFACTURERS LIFE INSURANCE COMPANY, THETRIM19,13910,990-42.6%$248.4K2026-Q1
FIFTH THIRD BANCORPDOUBLED8079,617+1091.7%$217.3K2026-Q1
Rockefeller Capital Management L.P.ADD8881,543+73.8%$34.9K2026-Q1
LOS ANGELES CAPITAL MANAGEMENT LLCNEAR_EXIT4,725279-94.1%$6.3K2026-Q1
HRT FINANCIAL LPNEAR_EXIT116,39518,384-84.2%$415.002026-Q1
Assenagon Asset Management S.A.EXIT435,1430-100.0%$0.002026-Q1
BALYASNY ASSET MANAGEMENT L.P.TRIM1,885,071945,979-49.8%$24.5M2025-Q4
TWO SIGMA INVESTMENTS, LPADD232,994451,852+93.9%$11.7M2025-Q4
Assenagon Asset Management S.A.ADD232,370435,143+87.3%$11.3M2025-Q4
DEUTSCHE BANK AG\NEW—387,540—$10.0M2025-Q4
Invesco Ltd.TRIM517,424244,679-52.7%$6.3M2025-Q4
FIRST TRUST ADVISORS LPDOUBLED9,742188,889+1838.9%$4.9M2025-Q4
15 unique insiders with 44 transactions. Net insider value: -$1.4M ($0.00 bought, $1.4M sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Jun 11, 2026RIKER LAURENSenior Vice President, FinanceSELL6,115$23.50$143.7K
Jun 10, 2026Brege LauraDirectorAWARD6,405——
Jun 10, 2026Froimson MarkDirectorAWARD6,405——
Jun 10, 2026CHRISTIE CHRISTOPHERDirectorAWARD6,405——
Jun 10, 2026WIGGANS THOMAS GDirectorAWARD32,675——
Jun 10, 2026CHRISTIE CHRISTOPHERDirectorAWARD10,891——
Jun 10, 2026YANG MICHAEL J.DirectorAWARD6,405——
Jun 10, 2026Young AlethiaDirectorAWARD6,405——
Jun 10, 2026YANG MICHAEL J.DirectorAWARD10,891——
Jun 10, 2026Young AlethiaDirectorAWARD10,891——
Jun 10, 2026Hirawat SamitDirectorAWARD6,405——
Jun 10, 2026BIGAL MARCELODirectorAWARD6,405——
Jun 10, 2026Brege LauraDirectorAWARD10,891——
Jun 10, 2026BIGAL MARCELODirectorAWARD10,891——
Jun 10, 2026Froimson MarkDirectorAWARD10,891——
Jun 10, 2026Hirawat SamitDirectorAWARD10,891——
Jun 4, 2026WILLIAMS KRISTENChief Administrative OfficerSELL10,259$22.27$228.5K
Jun 3, 2026SLONIN JONATHANChief Medical OfficerTAX W/H4,728$22.32$105.5K
Jun 3, 2026RIKER LAURENSenior Vice President, FinanceTAX W/H3,187$22.32$71.1K
Jun 3, 2026WILLIAMS KRISTENChief Administrative OfficerTAX W/H8,528$22.32$190.3K
Apr 23, 2026Cross ShawnChief Financial OfficerEXERCISE12,941$16.45$212.9K
Apr 23, 2026Cross ShawnChief Financial OfficerSELL12,941$25.16$325.6K
Apr 22, 2026Cross ShawnChief Financial OfficerEXERCISE1,500$16.45$24.7K
Apr 22, 2026Cross ShawnChief Financial OfficerSELL1,500$25.01$37.5K
Apr 21, 2026Cross ShawnChief Financial OfficerEXERCISE2,845$16.45$46.8K
Apr 21, 2026Cross ShawnChief Financial OfficerSELL2,845$25.01$71.2K
Apr 20, 2026Cross ShawnChief Financial OfficerEXERCISE7,714$16.45$126.9K
Apr 20, 2026Cross ShawnChief Financial OfficerSELL7,714$25.14$193.9K
Mar 17, 2026SLONIN JONATHANChief Medical OfficerSELL3,261$22.82$74.4K
Mar 17, 2026Froimson MarkDirectorSELL500$21.81$10.9K
Feb 11, 2026Cross ShawnChief Financial OfficerAWARD49,091——
Feb 11, 2026SLONIN JONATHANChief Medical OfficerAWARD54,546——
Feb 11, 2026WILLIAMS KRISTENChief Administrative OfficerAWARD54,546——
Feb 11, 2026Teehan BrendanChief Commercial OfficerAWARD51,714——
Feb 11, 2026RIKER LAURENSenior Vice President, FinanceAWARD19,273——
Feb 11, 2026Lee Frank D.Chief Executive OfficerAWARD261,818——
Feb 2, 2026RIKER LAURENSenior Vice President, FinanceSELL4,000$20.81$83.2K
Feb 2, 2026WILLIAMS KRISTENChief Administrative OfficerSELL13,137$20.53$269.7K
Jan 30, 2026SLONIN JONATHANChief Medical OfficerTAX W/H6,168$20.54$126.7K
Jan 30, 2026RIKER LAURENSenior Vice President, FinanceTAX W/H2,751$20.54$56.5K
Jan 30, 2026WILLIAMS KRISTENChief Administrative OfficerTAX W/H17,134$20.54$351.9K
Jan 30, 2026Teehan BrendanChief Commercial OfficerTAX W/H5,182$20.54$106.4K
Jan 30, 2026Lee Frank D.Chief Executive OfficerTAX W/H41,488$20.54$852.2K
Jun 11, 2025Kronenfeld Mark A.DirectorAWARD6,163——
10 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 5 mixed, 5 neutral. Avg impact: 4.6/10.
NEUTRAL CLUSTER 3/10
Pacira BioSciences saw two insider sales totaling $372K over a week, including the Chief Administrat
Jun 13, 2026
MIXED DEFA14A 6/10
Pacira BioSciences issued a DEFA14A press release reminding stockholders to vote FOR management's th
Jun 5, 2026
NEUTRAL 144 2/10
Kristen Williams, an officer of Pacira BioSciences, filed a Form 144 intent to sell 10,259 shares of
Jun 4, 2026
NEUTRAL DEFA14A 5/10
Pacira BioSciences issued a press release highlighting that ISS has recommended stockholders vote FO
Jun 1, 2026
MIXED DEFA14A 5/10
Pacira BioSciences issued a DEFA14A letter to stockholders ahead of its June 9, 2026 Annual Meeting,
May 27, 2026
MIXED DEFA14A 6/10
Pacira BioSciences issued a press release defending its intellectual property strategy against activ
May 26, 2026
MIXED DEFA14A 6/10
Pacira BioSciences filed additional definitive proxy soliciting materials (DEFA14A) urging stockhold
May 20, 2026
NEUTRAL 8-K 4/10
Pacira BioSciences reported Q1 2026 revenue of $177.4M (+5% YoY) and GAAP EPS of $0.07, down from $0
Apr 30, 2026
MIXED PREC14A 6/10
Pacira BioSciences is advancing its 5x30 strategy with strong commercial momentum, highlighted by 6.
Apr 17, 2026
NEUTRAL DEFA14A 3/10
Analysis based on filing metadata only — document content was unavailable. This DEFA14A filing for P
Mar 11, 2026
MIXED 7/10
Pacira BioSciences issued a press release urging stockholders to vote for its board nominees at the
May 20, 2026
BULLISH 7/10
Pacira BioSciences presented real-world data at AMCP 2026 showing EXPAREL® use in outpatient joint r
Apr 13, 2026
NEUTRAL 4/10
Pacira BioSciences responded to an activist investor, DOMA Perpetual Capital Management, which has n
Mar 11, 2026
Current analyst consensus: Buy (69% buy). Based on 13 analysts: 3 strong buy, 6 buy, 3 hold, 1 sell, 0 strong sell.

Analyst Price Targets

$29.67 mean target +29.0% upside Strong Buy (2.33)
$23.00 Low $38.00 High
MetricValue
Current Price$22.99
Target Low$23.00
Target Mean$29.67
Target Median$28.50
Target High$38.00
# Analysts6
RecommendationStrong Buy (2.33)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $0.65 $0.52 $0.76 -12.5% +2.4% 1↑ 6↓ $0.2B 5.5% 6
Next Q
2026-09-30
 $0.76 $0.64 $0.87 8.4% +1.3% 5↑ 1↓ $0.2B 6.2% 6
Current FY
2026-12-31
 $2.88 $2.74 $2.98 8.6% +0.7% 6↑ 1↓ $0.8B 5.7% 6
Next FY
2027-12-31
 $3.65 $3.18 $4.01 26.8% +0.9% 6↑ 1↓ $0.8B 8.3% 6

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$0.647
7d ago$0.650-0.003
30d ago$0.632+0.015
60d ago$0.711-0.063
90d ago$0.688-0.041
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
May 1, 2026 RBC Capital MAINTAIN Sector Perform Sector Perform
May 1, 2026 Needham MAINTAIN Buy Buy
Mar 26, 2026 Barclays MAINTAIN Equal-Weight Equal-Weight
Jan 9, 2026 HC Wainwright & Co. REITERATE Buy Buy
Jan 9, 2026 Needham MAINTAIN Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20263631069%
May 1, 20263631069%
Apr 1, 20263631069%
Mar 1, 20263631069%
Feb 1, 20263631069%
Jan 1, 20263631069%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 28, 2026
routine
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees
<p>BRISBANE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in it
May 27, 2026
other
Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees
<p align="center"><em>Clarifies DOMA’s Inaccuracies and the Reality of Pacira’ Efforts to Strengthen its Market Position</em></p>
May 20, 2026
activist
Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders
<p align="center"><em>Urges Stockholders to Vote “</em><strong><em>FOR</em></strong><em>” the Election of Pacira’s Highly Qualified Nominees on the </
May 20, 2026
Clinical Trial
Thoracic Epidural Analgesia vs Surgical Site Infiltration With Liposomal Bupivacaine Following Open Gynecologic Surgery
Phase Phase 3 — COMPLETED
May 13, 2026
other
Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences
<p>BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver inno
May 12, 2026
activist
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
<p align="center"><em>Highlights Nominees’ Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals</em></p>
May 8, 2026
other
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>BRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, no
May 5, 2026
earnings
Pacira BioSciences Mails Letter to Stockholders
<p align="center"><em>Details Success of Pacira’s 5x30 Strategy and Solid First Quarter 2026 Results </em></p>
May 1, 2026
short_volume
Short Volume: PCRX — 61.4% short (0.5M / 0.8M)
Short: 520,520 | Exempt: 40 | TRF Vol: 848,056 | Short Ratio: 61.4% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
earnings
Pacira BioSciences Reports First Quarter 2026 Financial Results
<p align="center"><em>-- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial po
Apr 30, 2026
earnings_calendar
PCRX Q1 2026 Earnings Scheduled — 2026-04-30
Apr 28, 2026
other
Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders
<p align="center"><em>Urges Stockholders to Vote “FOR” Pacira’s Highly Qualified Nominees on the </em><strong><em><u>BLUE</u></em></strong><em> Proxy
Apr 27, 2026
other
Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty
-- Findings show significant reductions in opioid consumption, healthcare resource utilization, and total medical costs -- <pre>-- Findings show signi
Apr 13, 2026
fda
Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures
<p align="center"><strong><em>-- Select findings demonstrate that the use of EXPAREL</em></strong><sup><strong><em>®</em></strong></sup><strong><em> (
Apr 7, 2026
Clinical Trial
A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain
Phase Phase 3 — COMPLETED
Mar 30, 2026
routine
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting
<p align="center"><em>-- Studies highlight reduced total cost of care and select healthcare resource utilization outcomes in total knee arthroplasty (
Mar 11, 2026
contract
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation
<p align="center"><em>-- Issues Statement in Response to DOMA’s Nomination of Director Candidates --</em></p> <p align="center"><em> -- No Shareholder